Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study.

ABSTRACT: Metastasis is the leading cause of cancer-related deaths. Voltage-gated sodium channels (VGSCs) regulate invasion and metastasis. Several VGSC-inhibiting drugs reduce metastasis in murine cancer models. We aimed to test the hypothesis that patients taking VGSC-inhibiting drugs who developed cancer live longer than those not taking these drugs. A cohort study was performed on primary care data from the QResearch database, including patients with breast, bowel or prostate cancer. Cox proportional hazards regression was used to compare the survival from cancer diagnosis of patients taking VGSC-inhibiting drugs with those not exposed to these drugs. Median time to death was 9.7 years in the exposed group and 18.4 years in the unexposed group, and exposure to these medications significantly inc

SUBMITTER: Fairhurst C 

PROVIDER: S-EPMC4649474 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature